Special NoticePosted Oct 22, 2026·Responses due Oct 30, 2026

Q301--NEW – STX Specialized Molecular Residual Disease Testing

Veterans Affairs · 257-NETWORK CONTRACT OFFICE 17 (36C257)

In plain words

Veterans Affairs is planning to buy "NEW – STX Specialized Molecular Residual Disease Testing". This is an early notice: it is not taking bids yet. Responses are due Oct 30, 2026. In the last 2 years, similar work went to 6 companies, usually for about $3.0M per award. An award is expected between December 2026 and February 2027.

Put together from the facts on this page; the details and sources are below.

Stage
Early notice (sources sought, presolicitation or special notice)
NAICS
621511
Value
Not stated
Solicitation
36C25727Q0058
Set-aside
None stated
PSC
Q301
Place
Not stated
Contact
Susan Flores (Susan.Flores2@va.gov)
…Open on SAM.gov
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 36C25727Q0058 in this department, oldest first.

Early notice
  • Oct 22, 2026 · this notice
    Special Notice
Solicitation
None posted
Award
Not yet. Typical award: Dec 6, 2026 to Feb 24, 2027, middle of the range Jan 23, 2027.
Measured from 44 past early notices at Veterans Affairs, Department of with NAICS 621511 that later posted an award (middle half of cases, counted from Oct 22, 2026).

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Answer the notice: this is when the requirement can still be shaped.
  • Contact the contracting officer named on the notice.
  • Check who won similar work; they are the likely bidders.

What the notice says

Special Notice Special Notice Page 3 of 3 Special Notice *= Required Field Special Notice Page 1 of 3 1. NOTICE OF INTENT DESCRIPTION The Department of Veterans Affairs, Network Contracting Office (NCO) 17, located at 5441 Babcock Road, Suite 302, San Antonio, TX 78229, intends to award an Indefinite Delivery Indefinite Quantity (IDIQ) Firm Fixed Price contract with five ordering periods on a sole-source basis to: Natera, Inc. 13011 McCallen Pass Austin, TX 78752 This requirement is for proprietary molecular genetic reference testing services used in the evaluation and monitoring of transplant… (show all)

patients and cancer residual disease. 2. SUPPLIES/SERVICES Item 0001 Description: Signatera Only, CPT Codes 81479, 81455 Estimated Quantity: 35 Unit: Each Item 0002 Description: Prospera, CPT Code 81479 Estimated Quantity: 25 Unit: Each Natera is the sole provider of these proprietary medical laboratory tests, including: Prospera molecular expression transplant assessment test Signatera Residual Disease Test (MRD) (non liquid biopsy tumor typing) No other vendor possesses the proprietary methodologies, assays, or intellectual property required to perform these tests. 3. SOLE SOURCE JUSTIFICATION Testing required by the VA is proprietary to Natera, Inc. No authorized distributors, third party laboratories, or alternative clinical sources exist for the Prospera and Signatera MRD tests. These assays cannot be substituted or performed by any other laboratory. Only Natera maintains the necessary technology, reagents, and bioinformatics platforms. 4. THIS NOTICE IS NOT A REQUEST FOR QUOTES This Special Notice is issued solely for information and planning purposes. It does not constitute a solicitation or a request for competitive quotes. Interested parties may submit a capability statement demonstrating an ability to perform the required testing. Responses must clearly show that an equivalent proprietary test exists and can be provided. 5. RESPONSE INSTRUCTIONS Responses must be emailed to: Susan Flores Contract Specialist, NCO 17 Email: Susan.Flores2@va.gov Deadline: November 2, 2026 at 10:00 AM CST The Government will review all responses but retains discretion regarding whether to compete this requirement. The Government is not responsible for any costs incurred in responding to this notice. 6. PLACE OF PERFORMANCE VA Facilities within VISN 17 (Texas) Specific ordering locations will be identified in individual task/delivery orders. 7. PERIOD OF PERFORMANCE Five ordering periods (exact dates to be determined at award).

Who won similar work

16 award notices on SAM.gov in the last 24 months. Matched by: Same office (257-NETWORK CONTRACT OFFICE 17 (36C257)), same product/service code (PSC) Q301 and NAICS 621511.

Single-winner award sizes (16): middle half $1.4M to $6.5M, median $3.0M; range $62K to $17.0M.

WinnerAwardsValueLast
QUEST DIAGNOSTICS INCORPORATED · $DGX · $11.6B8$49.6MMar 3, 2026
LABORATORY CORPORATION4$22.7MApr 27, 2026
PROPATH SERVICES, LLC1$4.0MJun 11, 2026
BEXAR COUNTY HOSPITAL DISTRICT SAN ANTONIO 782291$2.6MNov 20, 2024
ARUP LABORATORIES INC1$450KMar 19, 2025
AMBRY GENETICS CORPORATION1$62KFeb 26, 2026

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

Investor context
  • $DGX reported $11.6B revenue (12 months to Jun 30, 2026). The median single-winner award in these 16 past awards, $3.0M, is under 0.1% of that. SEC filing

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 6 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (0 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • $22K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 3 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.

Q301--NEW – STX Specialized Molecular Residual Disease Testing | HillSignal — HillSignal